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Abstract
HDL particles posses multiple antiatherogenic activities and the identification and differentiation of individual HDL
subclasses may be useful in documentation and understanding of metabolic changes of different HDL subclasses.
The major plasma lipids exist and are transported in the form of lipoprotein complexes. Hence, alterations in
plasma lipids levels can interfere with the composition, content, and distribution of plasma lipoprotein subclasses
that affect atherosclerosis risk. The research review major discussed the relationship between plasma lipids levels
and HDL subclasses distribution. The general shift toward smaller size of HDL particle size in HTG, HCL and MHL
subjects, and the changes were more prominent with the elevation of TG and TC levels which imply that HDL
maturation might be abnormal and RCT pathway might be weaken, and these changes were more seriously in
MHL subjects. Plasma contents of small sized HDL particles significantly higher, whereas those of large sized HDL
particles were significantly lower with elevation of TG/HDL-C and TC/HDL-C ratios. Increased in the TC/HDL-C ratio
alone did not influence the distributions of HDL subclasses significantly when the TG/HDL-C ratio was low (TG/
HDL-C ≤ 2.5). Hence, the TG/HDL-C ratio might be more sensitive to reflect the alteration of HDL subclass distribu-
tion than the TC/HDL-C ratio. In LDL-C/HDL-C ≤ 2.3 group, the pattern of distribution in HDL subclass was in
agreement with the normolipidemic subjects. Moreover, considering the relative ease of measuring TC/HDL-C, TG/
HDL-C and LDL-C/HDL-C ratios, as opposed to measuring HDL subclasses, these 3 ratios together may be a good
indicator of HDL subclass distribution. The protective effect of increased apoA-I levels against the reduction of
HDL2b caused by elevated TG concentration. On one hand, plasma HDL-C and apoA-I appear to play a coordinated
role in the assembly of HDL particles and the determination of their contents among the total subjects. On the
other hand, the apoA-I level might be a more powerful factor than HDL-C to influence the distribution of HDL
subclasses in hyperlipidemic subjects. At the same time, from point of HDL subclasses distribution, the plasma
lipids, apos concentrations and apos ratios should be considered while assessing the CHD risk. Abnormality of HDL
subclasses distribution may result in accelerated atherosclerosis, therapeutic normalization of attenuated antiathero-
genic HDL function in terms of both particle number and distribution of HDL particles is the target of innovative
pharmacological approaches to large-sized HDL particles rising, including enhanced apoA-I levels.
Introduction
It is well known that HDL does not represent a sum of
identical particles but is rather comprised of discrete sub-
classes that differ related to charge, density, size, compo-
sition, shape and physiological functions [1]. Using two-
dimensional gel electrophoresis coupled with immuno-
blotting, HDL can be divided into large, cholesterol-rich
(HDL2a and HDL2b), small-sized (HDL3c, HDL3b, HDL3a,
and preb1-HDL) and preb2-HDL [2,3]. Epidemiological
studies have shown that individual HDL subclasses are
not equally atheroprotective [4], a decrease content of
the large-sized HDL2b particles and an increase content
of the small-sized preb1-HDL particles were highly and
significantly associated with the risk of coronary heart
disease(CHD) [5,6].
Plasma lipoproteins have the general structure. The
hydrophobic cholesterol ester(CE) and triglyceride(TG)
occupy a core that is surrounded by a hydrophilic
* Correspondence: apolipoprotein2009@yahoo.com.cn
1Laboratory of Endocrinology and Metabolism, West China Hospital, Sichuan
University, Chengdu 610041, Sichuan, People’s Republic of China
Full list of author information is available at the end of the article
Tian and Fu Lipids in Health and Disease 2010, 9:118
http://www.lipidworld.com/content/9/1/118
© 2010 Tian and Fu; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
monomolecular surface layer of apolipoproteins(apos),
phospholipids(PL) and unesterified cholesterol [7]. So,
the abnormalities of plasma lipids and apos transport in
plasma will influence the composition and metabolism
of lipoproteins.
We have systematic illustrated the characteristics of
HDL subclasses distribution in different types of hyperli-
pidemic, obese subjects along with the effect of plasma
lipids ratio on HDL subclasses distribution [3,8-15]. The
characteristic of the transformation of HDL subclasses in
these patients appeared to be different, whereas there
was a general shift toward smaller sized HDL (preb1-
HDL increased while HDL2a and HDL2b decreased).
Furthermore, the association between the relative con-
centrations of apos and the various HDL subclasses also
investigated and reviewed [16-20]. The most significant
association was observed between the contents of all
HDL subclasses, especially large-sized HDL2b and apoA-
I. ApoA-II played a dual function in the contents of HDL
subclasses, and both small-sized HDL3b and HDL3a and
large-sized HDL2b tended to increase with apoA-II con-
centration. An increase in the concentrations of apoC-II,
C-III, and B-100 resulted in higher levels of small-sized
HDL particles and lower levels of large-sized HDL parti-
cles. Higher concentrations of apoA-I could inhibit the
reduction in the content of large-sized HDL2b effected by
apoB-100, C-II, and C-III. The content of preb1-HDL
increases significantly and that of HDL2b declines pro-
gressively with an increased apoB-100/apoA-I or a
decreased apoC-III/apoC-II ratio. In this research review
mainly describes the effect of plasma lipids concentra-
tions on HDL subclasses distribution profile.
Characteristics of distribution of HDL subclasses
for different types of hyperlipidemia
HDL metabolism is substantially altered in dyslipidemic
states, including hypertriglyceridemia (HTG), hypercholes-
terolemia (HCL), and mixed dyslipidemia (MHL). The
Figure 1 presented that the contents of major HDL sub-
classes (preb1-HDL, and HDL2b) distribution in normolipi-
demia, endogenous HTG, HCL along with MHL subjects.
Our previous investigations have found that although
there were some minor differences of HDL subclasses dis-
tribution in different types hyperlipidemia subjects, the
common tendency of increased small-sized and decreased
large-sized HDL particles was observed [3,8,9]. Aida, et al.
[21] test found that large subspecies (HDL2b, HDL2a) were
lower, and small (HDL3b, HDL3c) were higher in hyperlipi-
demia group than in normolipidemia group.
Endogenous hypertriglyceridemia and HDL subclasses
distribution profile
Endogenous HTG is commonly encountered hyperlipi-
demia in clinical practice, which is characterized by
elevation of TG and usually normal levels of TC. It is
reported that more than half of Chinese patients with
hyperlipidemia are endogenous HTG subjects. The pos-
sible reason is that diets high in carbohydrate are preva-
lent in China, which may result in disorder of TG
metabolism (excessive production and/or deficient clear-
ance) [22]. Epidemiologic studies provide increasing evi-
dence that plasma TG level is an important independent
risk indicator of CHD [23,24]. Miida, et al. [25] showed
that increased preb1-HDL contents at the expense of
HDL2b in HTG. Meanwhile, it is also reported that a
major subpopulation of HTG HDL had a mean diameter
of 8.4 ± 0.1 nm (HDL3) [26]. Some studies also found
that carbohydrate restriction significantly reduced TG
involved in TG metabolism, reduced the levels of
atherogenic lipoprotein particles, and increased the large
HDL particle size [27].
After a series of screening criteria, 176 subjects with
plasma TC < 6.21 mmol/L and TG ≥ 2.26 mmol/L were
defined as HTG subjects, small-sized preb1-HDL and
HDL3a were significantly higher; however, large-sized
HDL2a and HDL2b were significantly lower in HTG sub-
jects versus normolipidemic subjects. In addition, males
had significantly higher small-sized preb1-HDL and
HDL3b, but lower large-sized HDL2b than females in
both normolipidemic and HTG subjects [8].
Figure 1 Characteristics of major HDL subclasses (preb1-HDL,
and HDL2b) distribution in normolipidemia, endogenous
hypertriglyceridemic, hypercholesterolmic along with mixed
hyperlipidemic subjects. This chart contains data from references
[3,8,9], the mean of TG, and TC in normolipidemia,
hypertriglyceridemia, hypercholesteromia, and mixed hyperlipidemia
subjects, respectively, and their corresponds levels of preb1-HDL and
HDL2b were used to depict this chart. The mean TG and TC levels in
normolipidemic were 1.2 and 5 mmol/L, in hypertriglyceridemia
were 3.9 and 5.1 mmol/L, in hypercholesteromia were 1.4 and 6.9
mmol/L, and in mixed hyperlipidemia were 4.2 and 6.8 mmol/L,
respectively. Compared with normolipidemia subjects, the contents
of preb1-HDL increased significantly, however, those of HDL2b
decreased significant in hypertriglyceridemia, hypercholesteromia,
and mixed hyperlipidemia subjects. Moreover, Preb1-HDL increased
most prominent in mixed hyperlipidemia subjects, and HDL2b
decreased more apparent occurred in hypertriglyceridemia.
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To study the influence of plasma different TG levels
on HDL subclasses distribution, we divided the HTG
subjects into 2 groups, that is, high (2.26-5.64 mmol/L),
and very high ( ≥ 5.65 mmol/L) TG subjects; the nor-
molipidemic subjects(TG < 2.26 mmol/L and TC < 6.21
mmol/L) classified as normal (<1.69 mmol/L) and bor-
derline-high (1.69-2.25 mmol/L) TG subjects [8],
according to the third Report of NCEP (ATP-III) guide-
lines [28], and observed that with the elevation of TG
levels, the contents of small-sized preb1-HDL and
HDL3a increased successively, but those of large-sized
HDL2a andHDL2b decreased successively. Compared
with normal TG subjects, an increase (17%, 61%, and
124%) in preb1-HDL and a decrease (7%, 37%, and 52%)
in HDL2b were found in borderline-high, high and very
high TG subjects, respectively [8].
Mechanisms leading to reduced large sized HDL parti-
cles and increased small sized HDL particles in HTG
states are as follows: there is an increased mass transfer
of TG from TG-rich lipoproteins(TRL) to HDL particles
through the action of cholesteryl ester transfer protein
(CETP) [29], a process leading to TG enrichment of
HDL. TG-enriched HDL has been shown to be more
prone to lipolysis by hepatic lipase (HL), giving rise to
the formation of small, lipolytically modified HDL parti-
cles [30]. Moreover, some evidences have established
that with the increase of plasma TG concentration,
Lecithin-cholesterol acyltransferase (LCAT) and lipopro-
tein lipase (LPL) activities were impaired [31,14]. LCAT
may catalyze unesterified cholesterol to cholesterol ester
and promotes the conversion of preb1-HDL and HDL3
to HDL2. LPL plays an important role in hydrolyzing
TG transported in chylomicrons (CM) and very low
density lipoprotein(VLDL) particles. When catabolized
by LPL, CM and VLDL release TG, TC, phospholipids,
apoA-I, and apoC. Subsequent binding of these products
to HDL3 results in formation of HDL2 particles. There-
fore, impaired LCAT and LPL activities reduce esterifi-
cation of HDL-free TC, which resulted in abnormal
HDL maturation and consequently higher preb1-HDL
and HDL3a, as well as lower HDL2a and HDL2b. All
these observations demonstrated that plasma concentra-
tions of TG have significantly important effects on the
distributions of HDL subclasses and HDL maturation
might be abnormal and RCT might be weakened in
HTG subjects.
Hypercholesterolemia, combined hyperlipidemia HDL
subclasses distribution profile
HCL and MHL are common forms of atherogenic dysli-
poproteinemia. HCL is characterized by elevation of TC
and usually normal levels of TG while MHL is charac-
terized by concomitant increase of plasma levels of TC
and TG. Patients with HCL and with MHL have
different lipid phenotypes, and HDL metabolism is sub-
stantially altered in these dyslipidemic states, however,
are associated with accelerated atherosclerosis (As) [32].
By studying the characteristics of HDL subclasses dis-
tribution in HCL and MHL subjects, we found that both
in HCL and MHL subjects, all small HDL particles (pre-
b1-HDL, HDL3c, HDL3b and HDL3a) were significantly
elevated whereas large HDL particles (HDL2a and
HDL2b) were significantly reduced. Compared with nor-
molipidemic subjects, an increase (44.3%, and 104%) in
preb1-HDL and a decrease (24.6%, and 53.9%) in HDL2b
were found in HCL and MHL subjects, respectively. The
findings suggests that the trend toward smaller of HDL
size for MHL subjects was more obvious than HCL sub-
jects [30]. The HDL subclasses metabolism was also
reported by Saidi, et al. [33] the study included 11 MHL
and 11 HCL patients. In MHL compared with HCL
patients, decreased HDL2 levels were related to both
HDL2b and HDL2a subpopulations (-57% and -49%,
respectively, P < .01 for both). Moreover, in the study of
Hogue for example, the integrated HDL size was signifi-
cantly smaller in the familial HCL group compared to
controls. In each groups, men had smaller HDL particles
than women observed [34].
Numerous investigations have confirmed that eleva-
tion of TC level results in increased CHD risk
[28,35,36]. Most studies clearly showed that in HCL and
MHL subjects, CETP activity was high while LCAT
activity was low, which was associated with the
increased plasma TC level in these persons [37-39].
Above-mentioned, changes in these enzyme activities
resulted in raising preb1-HDL and HDL3a, as well as
decreasing HDL2a and HDL2b. Correlation analysis
revealed [9] that after controlling for sex, age, weight
and BMI, plasma TG, TC and LDL-C levels were posi-
tively and significantly correlated with small-sized preb1-
HDL while negatively and significantly correlated with
large-sized HDL2b not only in HCL but in MHL sub-
jects. In contrast, HDL-C levels showed positive correla-
tion with HDL2b only within MHL subjects. The
changes of HDL subclasses in MHL subjects also prob-
ably related to lower HDL-C level, which might lead to
the decrease of LCAT activity and increase of CETP
activity [40]. Consequently, reduction in HDL-C and
increases in TG as well as TC resulted in the more
marked increase of small sized HDL subclasses in MHL
subjects.
The TG and TC are two main types of lipids in
plasma. Alteration of their concentrations predicts that
the dynamic balance of plasma lipids metabolism was
destroyed, which certainly will induce the changes in
plasma lipoproteins along with their subclasses composi-
tion, contents and distribution. For grouped analyses,
individuals were classified according to approximately
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equal ninths of baseline TG and TC for the entire study
population (Unpublished data). Trends in mean values
of major HDL subclasses (preb1-HDL and HDL2b)
across these ninths were assessed through simple linear
regression, in this models with the contents of preb1-
HDL and HDL2b as the dependent variable and the
levels of TG as independent variable (Figure 2), which
exhibited that preb1-HDL contents is elevated about 9
mg/L and HDL2b contents can be reduced 21 mg/L for
0.5 mmol/L increment in TG; unlikeness, the levels of
TC were liner with HDL2b and HDL2b contents can be
reduced 17 mg/L for 0.5 mmol/L increment in TC.
Above evidence showed that the general shift toward
smaller size of HDL particle size in HTG, HCL and
MHL subjects, and the changes were more prominent
with the elevation of TG and TC levels. The changes
mentioned above imply that HDL maturation might be
abnormal and RCT pathway might be weaken, and
which were more seriously in MHL subjects.
Relationship between plasma lipids ratios and
HDL subclasses distribution
The Third Adult Treatment Panel guidelines of the US
National Cholesterol Education Program (ATP-III) [28]
Figure 2 The relationship between plasma TG, TC and HDL subclasses distribution. For grouped analyses, individuals were classified
according to approximately equal ninths of baseline TG and TC for the entire study population. Trends in mean values of major HDL subclasses
(preb1-HDL and HDL2b) across these ninths were assessed through simple linear regression, and using each stratum TG and TC median value as
x axis, with every stratum TG and TC corresponding the median preb1-HDL and HDL2b contents as y axis to plot. The results revealed that preb1-
HDL contents is elevated about 9 mg/L and HDL2b contents can be reduced 21 mg/L for 0.5 mmol/L increment in TG; unlikeness, the levels of
TC were liner with HDL2b and HDL2b contents can be reduced 17 mg/L for 0.5 mmol/L increment in TC.
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recommend a full fasting lipoprotein profile, including
TG, TC, HDL-C, and low-density lipoprotein cholesterol
(LDL-C). Although the guidelines only provide for eva-
luation of individual lipid fractions, the application of
ratios such as TC/HDL-C, TG/HDL-C, and LDL-C/
HDL-C may offer a refined risk assessment by simulta-
neously considering both anti-atherogenic and athero-
genic lipid parameters. The Figure 3 presented that the
relationship between plasma lipids ratios and HDL sub-
classes distribution [11,12].
Plasma TG/HDL-C and TC/HDL-C ratios and HDL
subclasses distribution profile
Some literatures indicate that elevated fasting TG repre-
sent a useful marker for risk of CHD, particularly when
HDL-C levels are considered [41]. The strong associa-
tion of the ratio of TG/HDL-C with risk of CHD sug-
gests a metabolic interaction between the TG- and
cholesterol ester-rich lipoproteins in increasing risk of
myocardial infarction (MI) [41]. Ratio of cholesterol
ester-rich lipoprotein levels (TC/HDL-C) is well-estab-
lished predictors of CHD [42], and a high ratio may be
a good indicator of abnormal cholesterol metabolism
and a 1-unit increase in the TC/HDL-C associated with
49% increases in risk of MI. Da Luz, et al. [43] study
indicates that TC/HDL-C ratio is an easy, non-invasive
means of predicting the presence and extent of coronary
atherosclerosis, and the ratio TG/HDL-C, initially pro-
posed by Gaziano, et al. [41] is an atherogenic index
that has proven to be a highly significant independent
predictor of MI even stronger than TC/HDL-C.
According to the ATP-III, 3 ranges of TC are defined:
less than 200, 200-240, and 240 mg/dL or greater; simi-
larly, 3 ranges of TG are defined: less than 150,150-200,
and 200 mg/dL or greater. In addition, low HDL-C
levels are designated as less than 40 mg/dL and high
levels as 60 mg/dL or greater [28]. In recent years, it has
been reported that risk for cardiac events is significantly
higher when the TC/HDL-C ratio is greater than 5;
Therefore, we make use of the TC/HDL-C ratio of 3.3
(200/60) and 6 (240/40) as the cutpoints and insert an
additional TC/HDL-C group ranging from 3.3 to 5 [11].
The subjects were divided into TC/HDL-C ≤ 3.3, 3.3 <
TC/HDL-C ≤ 5, 5 < TC/HDL-C ≤ 6, and TC/HDL-C >
6 groups. Likewise, TG/HDL-C ratios of 2.5 (150/60)
and 5 (200/40) were used as the cutpoints. The subjects
were divided into 3 groups: TG/HDL-C ≤ 2.5, 2.5 < TG/
HDL-C ≤ 5 and TG/HDL-C > 5 group [11].
Analyzing the relationship between the ratios of TC/
HDL-C, TG/HDL-C, and the alteration of HDL sub-
classes showed that, with the elevation of these ratios,
HDL particles shifted toward smaller sizes [35].
Figure 3 Association of plasma lipids ratios and distribution of HDL subclasses. This chart was constructed from data in references
[8,11,12]. With the elevation of TG/HDL-C, TC/HDL-C, and LDL-C/HDL-C ratios, the contents of small-sized preb1-HDL increased progressively, but
those of large-sized HDL2b decreased progressively. Moreover, the characteristic of HDL subclass distribution for subjects with TG/HDL-C, TC/HDL-
C, and LDL-C/HDL-C was 1.5, 3.0, and 1.7, respectively in accordance with that for the normolipidemic subject in our previous study. Especially,
the subjects with LDL-C/HDL-C > 5.6 group had significant higher preb1-HDL and significant lower HDL2b, which resulted in the ratio of HDL2b/
preb1-HDL from 4.8 in LDL-C/HDL-C < 1.7 group decreased to 1.4.
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Meanwhile, the characteristic of HDL subclass distribu-
tion for subjects with TC/HDL-C ≤ 3.3 or/and TG/
HDL-C ≤ 2.5 was in accordance with that for the nor-
molipidemic subject in our previous study [8,9,11,12].
Data obtained also suggest that, compared to the TC/
HDL-C ≤ 3.3 along with TG/HDL-C ≤ 2.5 group, small-
sized preb1-HDL increased significantly, whereas large-
sized HDL2b decreased significantly, which resulted in
an amazing reduction of HDL2b/preb1-HDL ratio (1.1 vs
4.7) and the percentage of large-sized HDL subclasses
(31.8% vs 53.4%) in the TC/HDL-C > 6 along with TG/
HDL-C > 5 group [11]. These findings revealed that
subjects with the high ratios of TC/HDL-C and TG/
HDL-C might have increased risk of CHD, because the
RCT might be weakened and the potential anti-athero-
genic functions of HDL might be impaired seriously
among these subjects.
As to the influence of change in the TC/HDL-C ratio
or the TG/HDL-C ratio on the apoA-I contents of
preb1-HDL and HDL2b which revealed that in the TG/
HDL-C ≤ 2.5 groups [11], regardless of whether the TC/
HDL-C ratios increased or not, both the preb1-HDL and
HDL2b were almost kept at constant levels. However, in
each same TC/HDL-C ratio group, preb1-HDL increased
significantly, whereas HDL2b decreased significantly with
the increase in the TG/HDL-C ratios. These observa-
tions implication that increase in the TC/HDL-C ratio
alone did not influence the distributions of HDL sub-
classes significantly when the TG/HDL-C ratio was low
(TG/HDL-C ≤ 2.5). Hence, the TG/HDL-C ratio might
be more sensitive to reflect the alteration of HDL sub-
class distribution than the TC/HDL-C ratio.
Plasma LDL-C/HDL-C ratio and HDL subclasses
distribution profile
There is overwhelming evidence [44,45] that an elevated
LDL-C concentration in plasma is atherogenic, whereas a
high HDL-C level is cardioprotective [45-47]. A series of
studies do suggest that use of the ratio of LDL-C to
HDL-C is superior to use of HDL-C or LDL-C alone [48]
and the ratio of LDL-C/HDL-C may provide better risk
assessment by concurrently accounting for both athero-
genic and protective lipid fractions. In the Physicians’
Health Study, a 1-unit increase in the LDL/HDL ratio
was associated with a 53% increase in risk of MI [49].
To assess the association of the LDL-C/HDL-C ratio
with HDL subclass distribution, The subjects categorized
into 4 subgroups ( ≤ 2.3, 2.3 to 3.9, 3.9 to 4.6, and >4.6)
based on the Quebec Cardiovascular Study and calcu-
lated odds ratios for ischemic heart disease (IHD) [12].
With the elevation of LDL-C/HDL-C ratio, the contents
of small-sized preb1-HDL, HDL3a, and HDL3b increased
progressively, but those of large-sized HDL2a and HDL2b
decreased progressively. In LDL-C/HDL-C ≤ 2.3 group,
the pattern of distribution in HDL subclass was in
agreement with the normolipidemic subjects [8]. Com-
pared with LDL-C/HDL-C ≤ 2.3 group, an increase
(50%, and 77%) in preb1-HDL and a decrease (48%, and
88%) in HDL2b were found in 3.9 < LDL-C/HDL-C ≤
4.6, and LDL-C/HDL-C > 4.6 groups, respectively [12].
Where it indicated that increased IHD risk in 3.9 to 4.6
and >4.6 of the LDL-C/HDL-C ratio (odds ratio 3.4 and
3.7, respectively) compared with IHD odds ratio for ≤
2.3 along with 2.3 to 3.9 of LDL-C/HDL-C subgroups
was 1.0 and 1.9, separately [50].
The HDL subclass distribution remodeling might
explained by increased LDL-C, TG, and decreased HDL-
C levels. The large majority of studies have implicated
that enhanced CETP and HL activities are correlated
with low HDL-C and high LDL-C levels [30,31,38,39].
On the other hand, a significant increase in TG levels
with a rise in LDL-C/HDL-C ratio also observed in this
study. It has been reported that high levels of TG are
associated with impaired LPL and LCAT activities
[31,14]. Take these all together suggested that high
LDL-C/HDL-C ratio was associated with low levels of
large-sized HDL2 and generally with small-sized HDL
particles.
An ideal ratio of LDL-C/HDL-C was 3.5 has been
used as markers of coronary atherosclerosis [51]. In this
context, the values of 3.5 were selected for LDL-C/
HDL-C ratio and ATPIII guidelines 2.26 mmol/L for
TG [28]as critical cutoff points to examine the joint
effect of LDL-C/HDL-C ratio together with TG levels
on change in HDL subclass distribution, which exhibit
that the particles of HDL subclasses tend to small in
LDL-C/HDL-C ≥ 3.5 group versus LDL-C/HDL-C < 3.5
group which indicated that abnormal metabolism of
HDL subclasses in LDL-C/HDL-C ≥ 3.5 group. Castelli,
et al. [51] observed that average LDL-C/HDL-C ratio for
people without CHD is less than 3.4, while value of the
ratio among patients with excessive rates of CHD is 3.5
or greater. In this regard, it is important to point out
that applying the LDL-C/HDL-C ratio to estimate the
risk of CHD should combine with effect of individual
TG levels.
Considering the relative ease of measuring TC/HDL-
C, TG/HDL-C and LDL-C/HDL-C ratios, as opposed to
measuring HDL subclasses, these 3 ratios together may
be a good indicator of HDL subclass distribution (and,
thus, cardiovascular disease risk).
The effect of plasma lipids combined with
apolipoproteins on HDL subclasses distribution
We have made a review of the association between the
relative concentrations of apos and the various HDL
subclasses [16-20]. The findings demonstrated that dif-
ferent apos have distinct influence on the profile of
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HDL subclasses distribution. In this research review, we
discussed the effect of plasma lipids coordinates with
apos on the profile of HDL subclasses distribution.
Plasma TG, apoA-I concentrations and HDL subclasses
distribution profile
On one hand, the TG-mediated alteration of HDL sub-
classes distribution involves specific interaction with
plasma enzyme activities, protein factor, and so on.
Another important metabolic trigger for HDL mature
metabolic disorder in the elevated TG concentrations
condition could be related to the plasma apos levels
alter. As a major protein component (about 70%) of
HDL, apoA-I promote cholesterol efflux from cells, and
through this mechanism may be important in maintain-
ing cellular cholesterol homeostasis [52]. Meanwhile,
apoA-I is not only activator of LCAT but also is a criti-
cal ligand of the HDL receptor SR-BI and the interac-
tion of apoA-I and SR-BI may facilitate hepatic selective
uptake of HDL-C in the RCT pathway hence play a vital
role in the maturation process of HDL subclasses
[53,54]. The apoA-I concentrations divided into tertiles
and TG levels by ATP-III guidelines to investigate the
influence of TG combined with apoA-I levels on pheno-
type of HDL subclasses distribution (Unpublished data).
The findings presented that regardless of elevated TG
and/or apoA-I, preb1-HDL contents were obviously
increased; Likeness, in any TG levels, the contents of
HDL2b significantly and gradually increased with elevated
of apoA-I levels, which suggested that the protective
effect of increased apoA-I levels against the reduction of
HDL2b caused by elevated TG concentration.
Plasma HDL-C, apoA-I concentrations and HDL subclasses
distribution profile
The studies also reported what degree of the HDL parti-
cles distribution was affected depend on a relatively
change between in HDL-C and apoA-I concentrations
[16]. All HDL subclasses contents increased gradually
and significantly, with elevated apoA-I along with
HDL-C levels, and the percentage of small-sized HDL
subclasses increased was low relative to that of the
large-sized HDL subclasses generally. Plasma HDL-C
and apoA-I appear to play a coordinated role in the
assembly of HDL particles and the determination of
their contents [16]. On the side, in each same apoA-I
group, regardless of the HDL-C concentrations both the
preb1-HDL and HDL2b were almost kept at the same
level. However, in each same HDL-C group, preb1-HDL
and HDL2b increased significantly with the increase of
apoA-I in hyperlipidemic subjects. It indicated that
apoA-I level might be a more powerful factor to influ-
ence the distribution in different HDL subclasses [13].
Recently, small, amphipathic helical apoA-I mimetic
peptides composed of D-amino acids have shown similar
antiatherogenic properties. Moreover, a specific apoA-I
mimetic peptide, D4F, has shown improved HDL-
mediated efflux and RCT from macrophages [55-57].
Plasma TG concentration, apoB-100/apoA-I ratio and HDL
subclasses distribution profile
The large prospective apolipoprotein-related Mortality
Risk (AMORIS) study [58] suggests that apoB-100,
apoA-I and the apoB-100/apoA-I ratio should be
regarded as highly predictive in evaluating cardiac risk
[58,59]. A series of studies have shown that an apoB-
100/apoA-I ratio ≥ 0.9 was a fair predictor of presence
of the metabolic syndrome (MetS) [60], and men with
an apoB-100/apoA-I ratio >0.9 had also a faster growth
of carotid artery intima-media thickness (IMT) than
those below this value [61]. Using a 0.9 cut-point for
the apoB-100/A-I ratio to dichotomize and analyze the
alteration of HDL subclasses distribution (Unpublished
data), and found the preb1-HDL contents increased sig-
nificantly and the HDL2b contents decreased signifi-
cantly as the elevation of TG concentration despite the
subjects with the apoB-100/apoA-I ratio < 0.9. At the
same time, in comparison with the normal TG, the
marked lower values of HDL2b/preb1-HDL in both high
and very high TG groups (5.3 vs 2.3, 1.7). Similarly, in
the apoB-100/apoA-I ratio ≥ 0.9, the HDL subclasses
distribution might be reversed for subjects with normal
TG concentration (Unpublished data). Although the
cholesterol balance determined as the apoB-100/apoA-I
ratio has repeatedly been shown to be a better index for
risk assessment of CHD, from the point of view of HDL
subclasses distribution, all these findings revealed that
when evaluation the CHD risk, relying only on the
apoB-100/apoA-I values for subjects might be inade-
quate and the concentration of TG should be
concerned.
In addition, to divide apoC-II into tertiles among the
whole population and the study showed compared to
the lowest tertile of apoC-II, the subjects with the high-
est tertile of apoC-II represent a typical HTG lipids pro-
file [17,18]. The higher TG concentrations were
associated with the levels of apoC-II and apoC-III
increased, and an increasing in apoC-II more prominent
than in apoC-III which conduces to the apoC-III/C-II
ratio declined. At the same time, there was a consistent
trend of increasing in contents of preb1-HDL whereas a
decreasing trend of in those of HDL2b with the reduc-
tion of apoC-III/C-II value. We also classified the apoB-
100 into tertiles in the total subjects and shed light on
the impact of changes in plasma apoB-100 levels on
HDL subclasses distribution. The findings were the con-
centrations of TC and TG were significantly increased
and HDL particles tend to smaller for subjects in the
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highest tertiles compared with those in the lowest ter-
tiles of apoB-100 [19]. So, from point of HDL subclasses
distribution, the plasma lipids together with apos con-
centrations should be considered while assessing the
CHD risk.
The antiatherogenic properties of HDL can, however
be compromised in dyslipidemic states associated with
elevated cardiovascular(CV) risk, therapeutic normaliza-
tion of attenuated antiatherogenic HDL function in
terms of both particle number and distribution of HDL
particles is the target of innovative pharmacological
approaches to large-sized HDL particles raising, includ-
ing enhanced apoA-I levels. Abnormality of HDL sub-
classes distribution may result in accelerated As, such
normalization of HDL metabolism can result from the
plasma lipids and apos alteration.
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